{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34707776", "DateCompleted": {"Year": "2022", "Month": "02", "Day": "07"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "10", "Day": "18"}], "Language": ["eng"], "ELocationID": ["3687700", "10.1155/2021/3687700"], "Journal": {"ISSN": "1942-0994", "JournalIssue": {"Volume": "2021", "PubDate": {"Year": "2021"}}, "Title": "Oxidative medicine and cellular longevity", "ISOAbbreviation": "Oxid Med Cell Longev"}, "ArticleTitle": "Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.", "Pagination": {"StartPage": "3687700", "MedlinePgn": "3687700"}, "Abstract": {"AbstractText": ["Paclitaxel is a broad-spectrum anticancer compound, which was derived mainly from a medicinal plant, in particular, from the bark of the yew tree <i>Taxus brevifolia</i> Nutt. It is a representative of a class of diterpene taxanes, which are nowadays used as the most common chemotherapeutic agent against many forms of cancer. It possesses scientifically proven anticancer activity against, e.g., ovarian, lung, and breast cancers. The application of this compound is difficult because of limited solubility, recrystalization upon dilution, and cosolvent-induced toxicity. In these cases, nanotechnology and nanoparticles provide certain advantages such as increased drug half-life, lowered toxicity, and specific and selective delivery over free drugs. Nanodrugs possess the capability to buildup in the tissue which might be linked to enhanced permeability and retention as well as enhanced antitumour influence possessing minimal toxicity in normal tissues. This article presents information about paclitaxel, its chemical structure, formulations, mechanism of action, and toxicity. Attention is drawn on nanotechnology, the usefulness of nanoparticles containing paclitaxel, its opportunities, and also future perspective. This review article is aimed at summarizing the current state of continuous pharmaceutical development and employment of nanotechnology in the enhancement of the pharmacokinetic and pharmacodynamic features of paclitaxel as a chemotherapeutic agent."], "CopyrightInformation": "Copyright \u00a9 2021 Javad Sharifi-Rad et al."}, "AuthorList": [{"Identifier": ["0000-0002-7301-8151"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Sharifi-Rad", "ForeName": "Javad", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Facultad de Ciencias de la Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, Iquique 1110939, Chile."}], "LastName": "Quispe", "ForeName": "Cristina", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Institute of Biotechnology & Medical Converged Science, Dongguk University, Goyangsi, Republic of Korea."}], "LastName": "Patra", "ForeName": "Jayanta Kumar", "Initials": "JK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Post-Harvest Technology, College of Horticulture and Forestry, Central Agricultural University, Pasighat, 791102 Arunachal Pradesh, India."}], "LastName": "Singh", "ForeName": "Yengkhom Disco", "Initials": "YD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Environment and Sustainability Department, CSIR-Institute of Minerals and Materials Technology, Bhubaneswar, 751013 Odisha, India."}], "LastName": "Panda", "ForeName": "Manasa Kumar", "Initials": "MK"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Institute of Biotechnology & Medical Converged Science, Dongguk University, Goyangsi, Republic of Korea."}], "LastName": "Das", "ForeName": "Gitishree", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Applied Microbiology, Biotechnology and Nanotechnology Laboratory, Department of Microbiology, Edo University Iyamho, PMB 04, Auchi, Edo State, Nigeria."}], "LastName": "Adetunji", "ForeName": "Charles Oluwaseun", "Initials": "CO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cardiometabolic Research Unit, Department of Physiology, College of Health Sciences, Bowen University, Iwo, Osun State, Nigeria."}], "LastName": "Michael", "ForeName": "Olugbenga Samuel", "Initials": "OS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Plant Biology Department, Institute of Biology, Taras Shevchenko National University of Kyiv, Kyiv 01033, Ukraine."}, {"Identifier": [], "Affiliation": "Department of Plant Physiology, Slovak University of Agriculture, Nitra 94976, Slovakia."}], "LastName": "Sytar", "ForeName": "Oksana", "Initials": "O"}, {"Identifier": ["0000-0001-8051-4981"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy."}], "LastName": "Polito", "ForeName": "Letizia", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute for Medicinal Plants Research \"Dr. Josif Pan\u010di\u0107\", Tadeu\u0161a Ko\u0161\u0107u\u0161ka 1, 11000 Belgrade, Serbia."}], "LastName": "\u017divkovi\u0107", "ForeName": "Jelena", "Initials": "J"}, {"Identifier": ["0000-0002-5934-5201"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Medicine, University of Porto, Porto, Portugal."}, {"Identifier": [], "Affiliation": "Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal."}, {"Identifier": [], "Affiliation": "Institute of Research and Advanced Training in Health Sciences and Technologies (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, PRD, Portugal."}], "LastName": "Cruz-Martins", "ForeName": "Nat\u00e1lia", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Pharmaceutical Botany, Jagiellonian University, Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland."}], "LastName": "Klimek-Szczykutowicz", "ForeName": "Marta", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Pharmaceutical Botany, Jagiellonian University, Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland."}], "LastName": "Ekiert", "ForeName": "Halina", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."}], "LastName": "Choudhary", "ForeName": "Muhammad Iqbal", "Initials": "MI"}, {"Identifier": ["0000-0003-2018-2406"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan."}, {"Identifier": [], "Affiliation": "Department of Pharmacognosy and Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Ayatollahi", "ForeName": "Seyed Abdulmajid", "Initials": "SA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biodiversity of Bioresources, Al-Farabi Kazakh National University, Almaty, Kazakhstan."}], "LastName": "Tynybekov", "ForeName": "Bekzat", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}, {"Identifier": [], "Affiliation": "Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}], "LastName": "Kobarfard", "ForeName": "Farzad", "Initials": "F"}, {"Identifier": ["0000-0001-9867-8394"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Banat's University of Agricultural Sciences and Veterinary Medicine \"King Michael I of Romania\" from Timisoara, Timisoara, Romania."}], "LastName": "Muntean", "ForeName": "Ana Covilca", "Initials": "AC"}, {"Identifier": ["0000-0002-2186-4364"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Banat's University of Agricultural Sciences and Veterinary Medicine \"King Michael I of Romania\" from Timisoara, Timisoara, Romania."}], "LastName": "Grozea", "ForeName": "Ioana", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Faculty of Science, Sivas Cumhuriyet University, 58140 Sivas, Turkey."}, {"Identifier": [], "Affiliation": "Beekeeping Development Application and Research Center, Sivas Cumhuriyet University, 58140 Sivas, Turkey."}], "LastName": "Da\u015ftan", "ForeName": "Sevgi Durna", "Initials": "SD"}, {"Identifier": ["0000-0002-2032-5000"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Banat's University of Agricultural Sciences and Veterinary Medicine \"King Michael I of Romania\" from Timisoara, Timisoara, Romania."}], "LastName": "Butnariu", "ForeName": "Monica", "Initials": "M"}, {"Identifier": ["0000-0002-6351-4047"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chair and Department of Pharmaceutical Botany, Jagiellonian University, Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland."}], "LastName": "Szopa", "ForeName": "Agnieszka", "Initials": "A"}, {"Identifier": ["0000-0002-1523-9116"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania."}], "LastName": "Calina", "ForeName": "Daniela", "Initials": "D"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "Oxid Med Cell Longev", "NlmUniqueID": "101479826", "ISSNLinking": "1942-0994"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}, {"RegistryNumber": "P88XT4IS4D", "NameOfSubstance": "Paclitaxel"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["adverse effects", "chemistry", "therapeutic use"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Drug Compounding"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Medical Oncology"}, {"QualifierName": [], "DescriptorName": "Nanomedicine"}, {"QualifierName": [], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["adverse effects", "chemistry", "therapeutic use"], "DescriptorName": "Paclitaxel"}], "CoiStatement": "The authors report no declarations of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Choudhury H., Maheshwari R., Pandey M., Takede M., Gorain B., Tekade R. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug \u2018Etoposide\u2019. Materials Science and Engineering: C . 2020;106, article 110275 doi: 10.1016/j.msec.2019.110275.", "ArticleIdList": ["10.1016/j.msec.2019.110275", "31753398"]}, {"Citation": "Perreira-Silva M., Alvarez-Lorenzo C., Concheiro A., Santos A., Veiga F., Figueiras A. Nanomedicine in osteosarcoma therapy: micelleplexes for delivery of nucleic acids and drugs toward osteosarcoma-targeted therapies. European Journal of Pharmaceutics and Biopharmaceutics . 2020;148:88\u2013106. doi: 10.1016/j.ejpb.2019.10.013.", "ArticleIdList": ["10.1016/j.ejpb.2019.10.013", "31958514"]}, {"Citation": "Roma-Rodrigues C., Rivas-Garc\u00eda L., Baptista P. V., Fernandes A. R. Gene therapy in cancer treatment: why go nano? Pharmaceutics . 2020;12(3):p. 233. doi: 10.3390/pharmaceutics12030233.", "ArticleIdList": ["10.3390/pharmaceutics12030233", "PMC7150812", "32151052"]}, {"Citation": "Yang Z., Ma Y., Zhao H., Yuan Y., Kim B. Nanotechnology platforms for cancer immunotherapy. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology . 2020;12(2, article e1590) doi: 10.1002/wnan.1590.", "ArticleIdList": ["10.1002/wnan.1590", "31696664"]}, {"Citation": "Feng B., Niu Z., Hou B., Zhou L., Li Y., Yu H. Enhancing triple negative breast cancer immunotherapy by ICG-templated self-assembly of paclitaxel nanoparticles. Advanced Functional Materials . 2019;30(6):1\u201313."}, {"Citation": "Salehi B., Lopez-Jornet P., Pons-Fuster L\u00f3pez E., et al. Plant-derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, aloe vera, green tea and coffee properties. Biomolecules . 2019;9(3):p. 106. doi: 10.3390/biom9030106.", "ArticleIdList": ["10.3390/biom9030106", "PMC6468600", "30884918"]}, {"Citation": "Jung Y. Y., Shanmugam M. K., Narula A. S., et al. Oxymatrine attenuates tumor growth and deactivates STAT5 signaling in a lung cancer xenograft model. Cancers . 2019;11(1):49\u201349. doi: 10.3390/cancers11010049.", "ArticleIdList": ["10.3390/cancers11010049", "PMC6356594", "30621055"]}, {"Citation": "Wilson B., Geetha K. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomedicine . 2020;15(5):433\u2013435. doi: 10.2217/nnm-2019-0366.", "ArticleIdList": ["10.2217/nnm-2019-0366", "31997697"]}, {"Citation": "Li Y. J., Wu J. Y., Wang J. M., Xiang D. X. Emerging nanomedicine-based strategies for preventing metastasis of pancreatic cancer. Journal of Controlled Release . 2020;320(January):105\u2013111. doi: 10.1016/j.jconrel.2020.01.041.", "ArticleIdList": ["10.1016/j.jconrel.2020.01.041", "31978441"]}, {"Citation": "Mukherjee A., Madamsetty V. S., Paul M. K., Mukherjee S. Recent advancements of nanomedicine towards antiangiogenic therapy in cancer. International Journal of Molecular Sciences . 2020;21(2):p. 455. doi: 10.3390/ijms21020455.", "ArticleIdList": ["10.3390/ijms21020455", "PMC7013812", "31936832"]}, {"Citation": "Russel L., Liu C., Grodzinski P. Nanomaterials innovation as an enabler for effective cancer interventions. Biomaterials . 2020;242, article 119926 doi: 10.1016/j.biomaterials.2020.119926.", "ArticleIdList": ["10.1016/j.biomaterials.2020.119926", "32169771"]}, {"Citation": "Ma P., Mumper R. Paclitaxel nano-delivery systems: a comprehensive review. Journal of nanomedicine & nanotechnology . 2013;4(2, article 1000164) doi: 10.4172/2157-7439.1000164.", "ArticleIdList": ["10.4172/2157-7439.1000164", "PMC3806207", "24163786"]}, {"Citation": "Della Corte L., Barra F., Foreste V., et al. Advances in paclitaxel combinations for treating cervical cancer. Expert Opinion on Pharmacotherapy . 2020;21(6):663\u2013677. doi: 10.1080/14656566.2020.1724284.", "ArticleIdList": ["10.1080/14656566.2020.1724284", "32037907"]}, {"Citation": "Caban-Toktas S., Sahin A., Lule S., et al. Combination of paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration. International Journal of Pharmaceutics . 2020;578:p. 119076. doi: 10.1016/j.ijpharm.2020.119076.", "ArticleIdList": ["10.1016/j.ijpharm.2020.119076", "31988035"]}, {"Citation": "Cheng Y., Ji Y. Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity. Journal of Controlled Release . 2020;318:38\u201349. doi: 10.1016/j.jconrel.2019.12.011.", "ArticleIdList": ["10.1016/j.jconrel.2019.12.011", "31830542"]}, {"Citation": "Sharifi-Rad J., Bahukhandi A., Dhyani P., et al. Therapeutic potential of neoechinulins and their derivatives: an overview of the molecular mechanisms behind pharmacological activities. Frontiers in Nutrition . 2021;8(July):1\u20138. doi: 10.3389/fnut.2021.664197.", "ArticleIdList": ["10.3389/fnut.2021.664197", "PMC8322439", "34336908"]}, {"Citation": "Iano\u0219i S., Batani A., Ilie M. A., et al. Non-invasive imaging techniques for the in vivo diagnosis of Bowen's disease: Three case reports. Oncology Letters . 2019;17(5):4094\u20134101. doi: 10.3892/ol.2019.10079.", "ArticleIdList": ["10.3892/ol.2019.10079", "PMC6444281", "30944602"]}, {"Citation": "Chabner B., Roberts T. Chemotherapy and the war on cancer. Nature Reviews. Cancer . 2005;5(1):65\u201372. doi: 10.1038/nrc1529.", "ArticleIdList": ["10.1038/nrc1529", "15630416"]}, {"Citation": "Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer? Journal of the National Cancer Institute . 2003;95(4):255\u2013257. doi: 10.1093/jnci/95.4.255.", "ArticleIdList": ["10.1093/jnci/95.4.255", "12591977"]}, {"Citation": "Strebhardt K., Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews. Cancer . 2008;8(6):473\u2013480. doi: 10.1038/nrc2394.", "ArticleIdList": ["10.1038/nrc2394", "18469827"]}, {"Citation": "Morales-Cruz M., Delgado Y., Castillo B., et al. Smart targeting to improve cancer therapeutics. Drug Design, Development and Therapy . 2019;Volume 13:3753\u20133772. doi: 10.2147/DDDT.S219489.", "ArticleIdList": ["10.2147/DDDT.S219489", "PMC6826196", "31802849"]}, {"Citation": "Buse J., El-Aneed A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine . 2010;5(8):1237\u20131260. doi: 10.2217/nnm.10.107.", "ArticleIdList": ["10.2217/nnm.10.107", "21039200"]}, {"Citation": "Huang H. C., Barua S., Sharma G., Dey S. K., Rege K. Inorganic nanoparticles for cancer imaging and therapy. Journal of Controlled Release . 2011;155(3):344\u2013357. doi: 10.1016/j.jconrel.2011.06.004.", "ArticleIdList": ["10.1016/j.jconrel.2011.06.004", "21723891"]}, {"Citation": "MaHam A., Tang Z., Wu H., Wang J., Lin Y. Protein-based nanomedicine platforms for drug delivery. Small . 2009;5(15):1706\u20131721. doi: 10.1002/smll.200801602.", "ArticleIdList": ["10.1002/smll.200801602", "19572330"]}, {"Citation": "Morachis J. M., Mahmoud E. A., Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacological Reviews . 2012;64(3):505\u2013519. doi: 10.1124/pr.111.005363.", "ArticleIdList": ["10.1124/pr.111.005363", "PMC3400833", "22544864"]}, {"Citation": "Hanahan D., Weinberg R. A. Hallmarks of cancer: the next generation. Cell . 2011;144(5):646\u2013674. doi: 10.1016/j.cell.2011.02.013.", "ArticleIdList": ["10.1016/j.cell.2011.02.013", "21376230"]}, {"Citation": "Salehi B., Shivaprasad Shetty M., Anil Kumar V. N., et al. Veronica plants\u2014drifting from farm to traditional healing, food application, and phytopharmacology. Molecules . 2019;24(13):p. 2454. doi: 10.3390/molecules24132454.", "ArticleIdList": ["10.3390/molecules24132454", "PMC6651156", "31277407"]}, {"Citation": "Hwang S. T., Kim C., Lee J. H., et al. Cycloastragenol can negate constitutive STAT3 activation and promote paclitaxel-induced apoptosis in human gastric cancer cells. Phytomedicine . 2019;59, article 152907 doi: 10.1016/j.phymed.2019.152907.", "ArticleIdList": ["10.1016/j.phymed.2019.152907", "30981183"]}, {"Citation": "Polito L., Djemil A., Bortolotti M. Plant toxin-based immunotoxins for cancer therapy: a short overview. Biomedicine . 2016;4:p. 12.", "ArticleIdList": ["PMC5344252", "28536379"]}, {"Citation": "Walsh V., Goodman J. From taxol to Taxol\u00ae: the changing identities and ownership of an anti-cancer drug. Medical anthropology . 2002;21(3\u20134):307\u2013336. doi: 10.1080/01459740214074.", "ArticleIdList": ["10.1080/01459740214074", "12458837"]}, {"Citation": "Renneberg R. Biotech history: yew trees, paclitaxel synthesis and fungi. Biotechnology Journal . 2007;2(10):1207\u20131209. doi: 10.1002/biot.200790106.", "ArticleIdList": ["10.1002/biot.200790106", "17935114"]}, {"Citation": "Atanasov A. A., Zotchev S. B., Dirsch V. M., Supuran C. T. Natural products in drug discovery: advances and opportunities. Nature Reviews. Drug Discovery . 2021;20(3):200\u2013216. doi: 10.1038/s41573-020-00114-z.", "ArticleIdList": ["10.1038/s41573-020-00114-z", "PMC7841765", "33510482"]}, {"Citation": "Liebmann J. E., Cook J. A., Lipschultz C., Teague D., Fisher J., Mitchell J. B. Cytotoxic studies of paclitaxel (Taxol\u00ae) in human tumour cell lines. British Journal of Cancer . 1993;68(6):1104\u20131109. doi: 10.1038/bjc.1993.488.", "ArticleIdList": ["10.1038/bjc.1993.488", "PMC1968657", "7903152"]}, {"Citation": "Manfredi J. J., Horwitz S. B. Taxol: an antimitotic agent with a new mechanism of action. Pharmacology & Therapeutics . 1984;25(1):83\u2013125. doi: 10.1016/0163-7258(84)90025-1.", "ArticleIdList": ["10.1016/0163-7258(84)90025-1", "6149569"]}, {"Citation": "Kingston D. G. I. Recent advances in the chemistry of taxol. Journal of Natural Products . 2000;63(5):726\u2013734. doi: 10.1021/np000064n.", "ArticleIdList": ["10.1021/np000064n", "10843603"]}, {"Citation": "Kingston D. G. I. The shape of things to come: structural and synthetic studies of taxol and related compounds. Phytochemistry . 2007;68(14):1844\u20131854. doi: 10.1016/j.phytochem.2006.11.009.", "ArticleIdList": ["10.1016/j.phytochem.2006.11.009", "PMC1979092", "17184797"]}, {"Citation": "Walsh V., Goodman J. Cancer chemotherapy, biodiversity, public and private property: the case of the anti-cancer drug Taxol. Social science and medicine . 1999;49(9):1215\u20131225. doi: 10.1016/S0277-9536(99)00161-6.", "ArticleIdList": ["10.1016/S0277-9536(99)00161-6", "10501642"]}, {"Citation": "Lee J. H., Kim C., Sethi G., Ahn K. S. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. Oncotarget . 2015;6(8):6386\u20136405. doi: 10.18632/oncotarget.3443.", "ArticleIdList": ["10.18632/oncotarget.3443", "PMC4467444", "25788267"]}, {"Citation": "Suffness M., Wall M. E. Discovery and development of taxol. In: Suffness M., editor. Taxol: Science and Applications . Boca Raton, Florida, USA: CRC Press; 1995. pp. 3\u201325."}, {"Citation": "Wiernik P. H., Schwartz E. L., Strauman J. J., Dutcher J. P., Lipton R. B., Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Research . 1987;47(9):2486\u20132493.", "ArticleIdList": ["2882837"]}, {"Citation": "Guenard D., Gueritte-Voegelein F., Dubois J., Potier P. Structure-activity relationships of Taxol and Taxotere analogues. Journal of the National Cancer Institute. Monographs . 1993;15:79\u201382.", "ArticleIdList": ["7912533"]}, {"Citation": "Kingston D. G. I. Taxol: the chemistry and structure-activity relationships of a novel anticancer agent. Trends in Biotechnology . 1994;12(6):222\u2013227. doi: 10.1016/0167-7799(94)90120-1.", "ArticleIdList": ["10.1016/0167-7799(94)90120-1", "7765351"]}, {"Citation": "Rowinsky E. K., Donehower R. C. Paclitaxel (Taxol) The New England Journal of Medicine . 1995;332(15):1004\u20131014. doi: 10.1056/NEJM199504133321507.", "ArticleIdList": ["10.1056/NEJM199504133321507", "7885406"]}, {"Citation": "Parness J., Horwitz S. B. Taxol binds to polymerized tubulin in vitro. The Journal of Cell Biology . 1981;91(2):479\u2013487. doi: 10.1083/jcb.91.2.479.", "ArticleIdList": ["10.1083/jcb.91.2.479", "PMC2111958", "6118377"]}, {"Citation": "Dammermann A., Desai A., Oegema K. The minus end in sight. Current Biology . 2003;13(15):R614\u2013R624. doi: 10.1016/S0960-9822(03)00530-X.", "ArticleIdList": ["10.1016/S0960-9822(03)00530-X", "12906817"]}, {"Citation": "Wiese C., Zheng Y. Microtubule nucleation: \u03b3-tubulin and beyond. Journal of Cell Science . 2006;119(20):4143\u20134153. doi: 10.1242/jcs.03226.", "ArticleIdList": ["10.1242/jcs.03226", "17038541"]}, {"Citation": "Ganguly A., Yang H., Cabral F. Paclitaxel-dependent cell lines reveal a novel drug activity. Molecular Cancer Therapeutics . 2010;9(11):2914\u20132923. doi: 10.1158/1535-7163.MCT-10-0552.", "ArticleIdList": ["10.1158/1535-7163.MCT-10-0552", "PMC2978777", "20978163"]}, {"Citation": "Schiff P. B., Fant J., Horwitz S. B. Promotion of microtubule assembly _in vitro_ by taxol. Nature . 1979;277(5698):665\u2013667. doi: 10.1038/277665a0.", "ArticleIdList": ["10.1038/277665a0", "423966"]}, {"Citation": "Zhang D., Yang R., Wang S., Dong Z. Paclitaxel: new uses for an old drug. Drug Design, Development and Therapy . 2014;8:279\u2013284.", "ArticleIdList": ["PMC3934593", "24591817"]}, {"Citation": "Rao S., Orr G. A., Chaudhary A. G., Kingston D. G. I., Horwitz S. B. Characterization of the Taxol Binding Site on the Microtubule: The Journal of Biological Chemistry . 1995;270(35):20235\u201320238. doi: 10.1074/jbc.270.35.20235.", "ArticleIdList": ["10.1074/jbc.270.35.20235", "7657589"]}, {"Citation": "Wang F., Cao Y., Zhao W. Z., Liu H., Fu Z., Han R. Taxol inhibits melanoma metastases through apoptosis induction, angiogenesis inhibition, and restoration of E-cadherin and nm23 expression. Journal of Pharmacological Sciences . 2003;93(2):197\u2013203. doi: 10.1254/jphs.93.197.", "ArticleIdList": ["10.1254/jphs.93.197", "14578588"]}, {"Citation": "Sevko A., Kremer V., Falk C., et al. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. Journal of Immunotoxicology . 2012;9(3):275\u2013281. doi: 10.3109/1547691X.2012.655343.", "ArticleIdList": ["10.3109/1547691X.2012.655343", "22449053"]}, {"Citation": "Kreis T., Vale R. Guidebook to the Cytoskeletal and Motor Proteins . 2nd. Oxford, UK: Oxford University Press; 1999."}, {"Citation": "Giannakakou P., Sackett D. L., Kang Y. K., et al. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant \u03b2-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization. The Journal of Biological Chemistry . 1997;272(27):17118\u201317125. doi: 10.1074/jbc.272.27.17118.", "ArticleIdList": ["10.1074/jbc.272.27.17118", "9202030"]}, {"Citation": "Rakovitch E., Mellado W., Hall E. J., Pandita T. K., Sawant S., Geard C. R. Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2/M accumulation. International Journal of Radiation Oncology \u2022 Biology \u2022 Physics . 1999;44(5):1119\u20131124. doi: 10.1016/S0360-3016(99)00109-1.", "ArticleIdList": ["10.1016/S0360-3016(99)00109-1", "10421546"]}, {"Citation": "Lowe S. W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science . 1994;266(5186):807\u2013810. doi: 10.1126/science.7973635.", "ArticleIdList": ["10.1126/science.7973635", "7973635"]}, {"Citation": "Zhang C. C., Yang J. M., White E., Murphy M., Levine A., Hait W. N. The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene . 1998;16(12):1617\u20131624. doi: 10.1038/sj.onc.1201658.", "ArticleIdList": ["10.1038/sj.onc.1201658", "9569030"]}, {"Citation": "Fukasawa K., Choi T., Kuriyama R., Rulong S., Woude G. F. V. Abnormal centrosome amplification in the absence of p53. Science . 1996;271(5256):1744\u20131747. doi: 10.1126/science.271.5256.1744.", "ArticleIdList": ["10.1126/science.271.5256.1744", "8596939"]}, {"Citation": "Wang T. H., Chan Y. H., Chen C. W., et al. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene . 2006;25(35):4857\u20134866. doi: 10.1038/sj.onc.1209498.", "ArticleIdList": ["10.1038/sj.onc.1209498", "16547493"]}, {"Citation": "Yakirevich E., Sabo E., Naroditsky I., Sova Y., Lavie O., Resnick M. B. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas. Gynecologic Oncology . 2006;100(1):152\u2013159. doi: 10.1016/j.ygyno.2005.08.050.", "ArticleIdList": ["10.1016/j.ygyno.2005.08.050", "16198399"]}, {"Citation": "Szak\u00e1cs G., Paterson J. K., Ludwig J. A., Booth-Genthe C., Gottesman M. M. Targeting multidrug resistance in cancer. Nature Reviews. Drug Discovery . 2006;5(3):219\u2013234. doi: 10.1038/nrd1984.", "ArticleIdList": ["10.1038/nrd1984", "16518375"]}, {"Citation": "Pfannenstiel L. W., Lam S. S. K., Emens L. A., Jaffee E. M., Armstrong T. D. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cellular Immunology . 2010;263(1):79\u201387. doi: 10.1016/j.cellimm.2010.03.001.", "ArticleIdList": ["10.1016/j.cellimm.2010.03.001", "PMC2862830", "20346445"]}, {"Citation": "Klauber N., Parangi S., Flynn E., Hamel E., D\u2019Amato R. J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Research . 1997;57(1):81\u201386.", "ArticleIdList": ["8988045"]}, {"Citation": "Belotti D., Vergani V., Drudis T., et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clinical Cancer Research . 1996;2(11):1843\u20131849.", "ArticleIdList": ["9816139"]}, {"Citation": "Lau D. H., Xue L., Young L. J., Burke P. A., Cheung A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biotherapy & Radiopharmaceuticals . 1999;14(1):31\u201336. doi: 10.1089/cbr.1999.14.31.", "ArticleIdList": ["10.1089/cbr.1999.14.31", "10850285"]}, {"Citation": "Jiang X. Harnessing the immune system for the treatment of breast cancer. Journal of Zhejiang University. Science. B . 2014;15(1):1\u201315. doi: 10.1631/jzus.B1300264.", "ArticleIdList": ["10.1631/jzus.B1300264", "PMC3891115", "24390741"]}, {"Citation": "Loffler T. M., Freund W., Lipke J., Hausamen T. U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Seminars in Oncology . 1996;23(6 suppl 16):32\u201334.", "ArticleIdList": ["9007118"]}, {"Citation": "Abu-Rustum N. R., Aghajanian C., Barakat R. R., Fennelly D., Shapiro F., Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Seminars in Oncology . 1997;24(5 suppl 15)", "ArticleIdList": ["9346225"]}, {"Citation": "Alexandre J., Hu Y., Lu W., Pelicano H., Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Research . 2007;67(8):3512\u20133517. doi: 10.1158/0008-5472.CAN-06-3914.", "ArticleIdList": ["10.1158/0008-5472.CAN-06-3914", "17440056"]}, {"Citation": "Hadzic T., Aykin-Burns N., Zhu Y., et al. Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radical Biology & Medicine . 2010;48(8):1024\u20131033. doi: 10.1016/j.freeradbiomed.2010.01.018.", "ArticleIdList": ["10.1016/j.freeradbiomed.2010.01.018", "PMC2843822", "20083194"]}, {"Citation": "Newman D. J., Cragg G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products . 2020;83(3):770\u2013803. doi: 10.1021/acs.jnatprod.9b01285.", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Pinzaru I., Coricovac D., Dehelean C., et al. Stable PEG-coated silver nanoparticles - A comprehensive toxicological profile. Food and Chemical Toxicology . 2018;111:546\u2013556. doi: 10.1016/j.fct.2017.11.051.", "ArticleIdList": ["10.1016/j.fct.2017.11.051", "29191727"]}, {"Citation": "Docea A. O., Calina D., Buga A. M., et al. The effect of silver nanoparticles on antioxidant/pro-oxidant balance in a murine model. International Journal of Molecular Sciences . 2020;21(4):p. 1233. doi: 10.3390/ijms21041233.", "ArticleIdList": ["10.3390/ijms21041233", "PMC7072874", "32059471"]}, {"Citation": "Wang R., Billone P. S., Mullett W. M. Catalytic Properties of Pd Modified Cu/SAPO-34 for Removal from Diesel Engine. Journal of Nanomaterials . 2013;2013:9. doi: 10.1155/2013/625739.", "ArticleIdList": ["10.1155/2013/625739"]}, {"Citation": "Wang J., Liu W., Tu Q., et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery. Biomacromolecules . 2011;12(1):228\u2013234. doi: 10.1021/bm101206g.", "ArticleIdList": ["10.1021/bm101206g", "21158381"]}, {"Citation": "Mohamed F., Marchettini P., Stuart O. A., Sugarbaker P. H. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemotherapy and Pharmacology . 2003;52(5):405\u2013410. doi: 10.1007/s00280-003-0680-2.", "ArticleIdList": ["10.1007/s00280-003-0680-2", "12879282"]}, {"Citation": "Luo J., Liu L., Wu C. D. Enhancement of paclitaxel production by abscisic acid in cell suspension cultures of Taxus chinensis. Biotechnology Letters . 2001;23(16):1345\u20131348. doi: 10.1023/A:1010597802741.", "ArticleIdList": ["10.1023/A:1010597802741"]}, {"Citation": "Yu Y. H., Kim E., Park D. E., et al. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA. European Journal of Pharmaceutics and Biopharmaceutics . 2012;80(2):268\u2013273. doi: 10.1016/j.ejpb.2011.11.002.", "ArticleIdList": ["10.1016/j.ejpb.2011.11.002", "22108492"]}, {"Citation": "Bajaj G., Kim M. R., Mohammed S. I., Yeo Y. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release . 2012;158(3):386\u2013392. doi: 10.1016/j.jconrel.2011.12.001.", "ArticleIdList": ["10.1016/j.jconrel.2011.12.001", "PMC3319161", "22178261"]}, {"Citation": "Emoto S., Yamaguchi H., Kamei T., et al. Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surgery Today . 2014;44(5):919\u2013926. doi: 10.1007/s00595-013-0674-6.", "ArticleIdList": ["10.1007/s00595-013-0674-6", "23887848"]}, {"Citation": "Salehi B., Calina D., Docea A., et al. Curcumin\u2019s nanomedicine formulations for therapeutic application in neurological diseases. Journal of Clinical Medicine . 2020;9(2):p. 430. doi: 10.3390/jcm9020430.", "ArticleIdList": ["10.3390/jcm9020430", "PMC7074182", "32033365"]}, {"Citation": "Matei A. M., Caruntu C., Tampa M., et al. Applications of nanosized-lipid-based drug delivery systems in wound care. Applied Sciences . 2021;11(11):p. 4915. doi: 10.3390/app11114915.", "ArticleIdList": ["10.3390/app11114915"]}, {"Citation": "Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research . 1986;46(12):6387\u20136392.", "ArticleIdList": ["2946403"]}, {"Citation": "Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release . 2000;65(1-2):271\u2013284. doi: 10.1016/S0168-3659(99)00248-5.", "ArticleIdList": ["10.1016/S0168-3659(99)00248-5", "10699287"]}, {"Citation": "Bregoli L., Movia D., Gavigan-Imedio J. D., Lysaght J., Reynolds J., Prina-Mello A. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomedicine: Nanotechnology, Biology and Medicine . 2016;12(1):81\u2013103. doi: 10.1016/j.nano.2015.08.006.", "ArticleIdList": ["10.1016/j.nano.2015.08.006", "26370707"]}, {"Citation": "Kitayama J., Ishigami H., Yamaguchi H., et al. Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model. Pleura and Peritoneum . 2017;2(2):95\u2013102. doi: 10.1515/pp-2017-0002.", "ArticleIdList": ["10.1515/pp-2017-0002", "PMC6405031", "30911637"]}, {"Citation": "Tanei T., Leonard F., Liu X., et al. Redirecting transport of nanoparticle albumin-bound paclitaxel to macrophages enhances therapeutic efficacy against liver metastases. Cancer Research . 2016;76(2):429\u2013439. doi: 10.1158/0008-5472.CAN-15-1576.", "ArticleIdList": ["10.1158/0008-5472.CAN-15-1576", "PMC4715951", "26744528"]}, {"Citation": "Yang J., Lv Q., Wei W., et al. Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy. Drug Delivery . 2018;25(1):807\u2013814. doi: 10.1080/10717544.2018.1451935.", "ArticleIdList": ["10.1080/10717544.2018.1451935", "PMC6058529", "29553858"]}, {"Citation": "Lei M., Sha S., Wang X., et al. Co-delivery of paclitaxel and gemcitabineviaa self-assembling nanoparticle for targeted treatment of breast cancer. RSC Advances . 2019;9(10):5512\u20135520. doi: 10.1039/C9RA00276F.", "ArticleIdList": ["10.1039/C9RA00276F", "PMC9060788", "35515924"]}, {"Citation": "Gogat\u00e9 U. S., Schwartz P. A., Agharkar S. N. Effect of unpurified cremophor EL on the solution stability of paclitaxel. Pharmaceutical Development and Technology . 2009;14(1):1\u20138. doi: 10.1080/10837450802409354.", "ArticleIdList": ["10.1080/10837450802409354", "18791935"]}, {"Citation": "Zhang J. A., Anyarambhatla G., Ma L., et al. Development and characterization of a novel Cremophor\u00ae EL free liposome-based paclitaxel (LEP-ETU) formulation. European Journal of Pharmaceutics and Biopharmaceutics . 2005;59(1):177\u2013187. doi: 10.1016/j.ejpb.2004.06.009.", "ArticleIdList": ["10.1016/j.ejpb.2004.06.009", "15567316"]}, {"Citation": "Wang F., Porter M., Konstantopoulos A., Zhang P., Cui H. Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy. Journal of Controlled Release . 2017;267:100\u2013118. doi: 10.1016/j.jconrel.2017.09.026.", "ArticleIdList": ["10.1016/j.jconrel.2017.09.026", "PMC5723209", "28958854"]}, {"Citation": "Paciotti G. F., Zhao J., Cao S., et al. Synthesis and evaluation of paclitaxel-loaded gold nanoparticles for tumor-targeted drug delivery. Bioconjugate Chemistry . 2016;27(11):2646\u20132657. doi: 10.1021/acs.bioconjchem.6b00405.", "ArticleIdList": ["10.1021/acs.bioconjchem.6b00405", "PMC5356508", "27689882"]}, {"Citation": "Wang X. S., Zhang L., Li X., et al. Nanoformulated paclitaxel and AZD9291 synergistically eradicate non-small-cell lung cancers in vivo. Nanomedicine . 2018;13(10):1107\u20131120. doi: 10.2217/nnm-2017-0355.", "ArticleIdList": ["10.2217/nnm-2017-0355", "PMC6219431", "29874151"]}, {"Citation": "Takashima T., Kawajiri H., Nishimori T., et al. Safety and efficacy of low-dose nanoparticle albumin-bound paclitaxel for HER2-negative metastatic breast cancer. Anticancer Research . 2018;38(1):379\u2013383. doi: 10.21873/anticanres.12233.", "ArticleIdList": ["10.21873/anticanres.12233", "29277798"]}, {"Citation": "Zong Y., Wu J., Shen K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget . 2017;8(10):17360\u201317372. doi: 10.18632/oncotarget.14477.", "ArticleIdList": ["10.18632/oncotarget.14477", "PMC5370046", "28061451"]}, {"Citation": "Ma W. W., Hidalgo M. The winning formulation: the development of paclitaxel in pancreatic cancer. Clinical Cancer Research . 2013;19(20):5572\u20135579. doi: 10.1158/1078-0432.CCR-13-1356.", "ArticleIdList": ["10.1158/1078-0432.CCR-13-1356", "23918602"]}, {"Citation": "Munagala R., Aqil F., Jeyabalan J., Gupta R. C. Bovine milk-derived exosomes for drug delivery. Cancer Letters . 2016;371(1):48\u201361. doi: 10.1016/j.canlet.2015.10.020.", "ArticleIdList": ["10.1016/j.canlet.2015.10.020", "PMC4706492", "26604130"]}, {"Citation": "Bastiancich C., Bozzato E., Luyten U., Danhier F., Bastiat G., Pr\u00e9at V. Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment. International Journal of Pharmaceutics . 2019;559:220\u2013227. doi: 10.1016/j.ijpharm.2019.01.042.", "ArticleIdList": ["10.1016/j.ijpharm.2019.01.042", "30703501"]}, {"Citation": "Bernabeu E., Helguera G., Legaspi M. J., et al. Paclitaxel-loaded PCL-TPGS nanoparticles: _In vitro_ and _in vivo_ performance compared with Abraxane \u00ae. Colloids and Surfaces. B, Biointerfaces . 2014;113:43\u201350. doi: 10.1016/j.colsurfb.2013.07.036.", "ArticleIdList": ["10.1016/j.colsurfb.2013.07.036", "24060929"]}, {"Citation": "Zhao T., Chen H., Dong Y., et al. Paclitaxel-loaded poly(glycolide-co-\u03b5-caprolactone)-b-D-\u03b1-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy. International Journal of Nanomedicine . 2013;8:1947\u20131957. doi: 10.2147/IJN.S44220.", "ArticleIdList": ["10.2147/IJN.S44220", "PMC3658437", "23696703"]}, {"Citation": "Ganipineni L. P., Ucakar B., Joudiou N., et al. Magnetic targeting of paclitaxel-loaded poly(lactic-co-glycolic acid)-based nanoparticles for the treatment of glioblastoma. International Journal of Nanomedicine . 2018;Volume 13:4509\u20134521. doi: 10.2147/IJN.S165184.", "ArticleIdList": ["10.2147/IJN.S165184", "PMC6092128", "30127603"]}, {"Citation": "Gong C., Xie Y., Wu Q., et al. Improving anti-tumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale . 2012;4(19):6004\u20136017. doi: 10.1039/c2nr31517c.", "ArticleIdList": ["10.1039/c2nr31517c", "22910790"]}, {"Citation": "Gorain B., Choudhury H., Pandey M., Kesharwani P. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Materials Science and Engineering: C . 2018;91:868\u2013880. doi: 10.1016/j.msec.2018.05.054.", "ArticleIdList": ["10.1016/j.msec.2018.05.054", "30033322"]}, {"Citation": "Bernabeu E., Gonzalez L., Legaspi M. J., Moretton M. A., Chiappetta D. A. Paclitaxel-loaded TPGS-b-PCL nanoparticles: in vitro cytotoxicity and cellular uptake in MCF-7 and MDA-MB-231 cells versus mPEG-b-PCL nanoparticles and Abraxane\u00ae. Journal of Nanoscience and Nanotechnology . 2016;16(1):160\u2013170. doi: 10.1166/jnn.2016.10739.", "ArticleIdList": ["10.1166/jnn.2016.10739", "27398441"]}, {"Citation": "Thu H. P., Nam N. H., Quang B. T., Son H. A., Toan N. L., Quang D. T. _In vitro_ and _in vivo_ targeting effect of folate decorated paclitaxel loaded PLA -TPGS nanoparticles. Saudi Pharmaceutical Journal . 2015;23(6):683\u2013688. doi: 10.1016/j.jsps.2015.02.002.", "ArticleIdList": ["10.1016/j.jsps.2015.02.002", "PMC4669427", "26702264"]}, {"Citation": "Wang K., Guo L., Xiong W., Sun L., Zheng Y. Nanoparticles of star-like copolymer mannitol-functionalized poly(lactide)-vitamin E TPGS for delivery of paclitaxel to prostate cancer cells. Journal of Biomaterials Applications . 2014;29(3):329\u2013340. doi: 10.1177/0885328214527486.", "ArticleIdList": ["10.1177/0885328214527486", "24621530"]}, {"Citation": "Parayath N. N., Nehoff H., Norton S. E., et al. Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model. International Journal of Nanomedicine . 2016;11:3979\u20133991. doi: 10.2147/IJN.S110251.", "ArticleIdList": ["10.2147/IJN.S110251", "PMC4993259", "27574427"]}, {"Citation": "Hu B., Yan Y., Tong F., et al. Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer. International Journal of Nanomedicine . 2018;Volume 13:3625\u20133640. doi: 10.2147/IJN.S166438.", "ArticleIdList": ["10.2147/IJN.S166438", "PMC6027826", "29983558"]}, {"Citation": "Pei Q., Hu X., Liu S., Li Y., Xie Z., Jing X. Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. Journal of Controlled Release . 2017;254:23\u201333. doi: 10.1016/j.jconrel.2017.03.391.", "ArticleIdList": ["10.1016/j.jconrel.2017.03.391", "28359677"]}, {"Citation": "Song Y., Cai H., Yin T., et al. Paclitaxel-loaded redox-sensitive nanoparticles based on hyaluronic acid-vitamin E succinate conjugates for improved lung cancer treatment. International Journal of Nanomedicine . 2018;Volume 13:1585\u20131600. doi: 10.2147/IJN.S155383.", "ArticleIdList": ["10.2147/IJN.S155383", "PMC5858821", "29588586"]}, {"Citation": "Guo S., Vieweger M., Zhang K., et al. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy. Nature Communications . 2020;11(1):p. 972. doi: 10.1038/s41467-020-14780-5.", "ArticleIdList": ["10.1038/s41467-020-14780-5", "PMC7033104", "32080195"]}, {"Citation": "Din F. U., Aman W., Ullah I., et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. International Journal of Nanomedicine . 2017;Volume 12:7291\u20137309. doi: 10.2147/IJN.S146315.", "ArticleIdList": ["10.2147/IJN.S146315", "PMC5634382", "29042776"]}, {"Citation": "Chen Z., Zheng Y., Shi Y., Cui Z. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. International Journal of Nanomedicine . 2018;Volume 13:319\u2013336. doi: 10.2147/IJN.S149196.", "ArticleIdList": ["10.2147/IJN.S149196", "PMC5768424", "29391792"]}, {"Citation": "Grivennikov S. I., Greten F. R., Karin M. Immunity, inflammation, and cancer. Cell . 2010;140(6):883\u2013899. doi: 10.1016/j.cell.2010.01.025.", "ArticleIdList": ["10.1016/j.cell.2010.01.025", "PMC2866629", "20303878"]}, {"Citation": "Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature . 2008;454(7203):436\u2013444. doi: 10.1038/nature07205.", "ArticleIdList": ["10.1038/nature07205", "18650914"]}, {"Citation": "Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annual Review of Immunology . 2012;30(1):677\u2013706. doi: 10.1146/annurev-immunol-020711-075008.", "ArticleIdList": ["10.1146/annurev-immunol-020711-075008", "22224761"]}, {"Citation": "Sharifi-Rad M., Anil Kumar N. V., Zucca P., et al. Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of chronic diseases. Frontiers in Physiology . 2020;11:1\u201321. doi: 10.3389/fphys.2020.00694.", "ArticleIdList": ["10.3389/fphys.2020.00694", "PMC7347016", "32714204"]}, {"Citation": "Kadariya Y., Menges C. W., Talarchek J., et al. Inflammation-related IL1\u03b2/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prevention Research . 2016;9(5):406\u2013414. doi: 10.1158/1940-6207.CAPR-15-0347.", "ArticleIdList": ["10.1158/1940-6207.CAPR-15-0347", "PMC4854753", "26935421"]}, {"Citation": "Takahashi H., Ogata H., Nishigaki R., Broide D. H., Karin M. Tobacco Smoke Promotes Lung Tumorigenesis by Triggering IKK\u03b2\\- and JNK1-Dependent Inflammation. Cancer Cell . 2010;17(1):89\u201397. doi: 10.1016/j.ccr.2009.12.008.", "ArticleIdList": ["10.1016/j.ccr.2009.12.008", "PMC2818776", "20129250"]}, {"Citation": "Quail D. F., Dannenberg A. J. The obese adipose tissue microenvironment in cancer development and progression. Nature Reviews. Endocrinology . 2019;15(3):139\u2013154. doi: 10.1038/s41574-018-0126-x.", "ArticleIdList": ["10.1038/s41574-018-0126-x", "PMC6374176", "30459447"]}, {"Citation": "Quail D. F., Olson O. C., Bhardwaj P., et al. Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. Nature Cell Biology . 2017;19(8):974\u2013987. doi: 10.1038/ncb3578.", "ArticleIdList": ["10.1038/ncb3578", "PMC6759922", "28737771"]}, {"Citation": "Albrengues J., Shields M. A., Ng D., et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science . 2018;361(6409, article eaao4227) doi: 10.1126/science.aao4227.", "ArticleIdList": ["10.1126/science.aao4227", "PMC6777850", "30262472"]}, {"Citation": "Canli \u00d6., Nicolas A. M., Gupta J., et al. Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell . 2017;32(6):869\u2013883.e5. doi: 10.1016/j.ccell.2017.11.004.", "ArticleIdList": ["10.1016/j.ccell.2017.11.004", "29232557"]}, {"Citation": "Chang W. C. I., Coudry R. A., Clapper M. I., et al. Loss of p53 enhances the induction of colitis-associated neoplasia by dextran sulfate sodium. Carcinogenesis . 2007;28(11):2375\u20132381. doi: 10.1093/carcin/bgm134.", "ArticleIdList": ["10.1093/carcin/bgm134", "17557903"]}, {"Citation": "Hussain S. P., Hofseth L. J., Harris C. C. Radical causes of cancer. Nature Reviews. Cancer . 2003;3(4):276\u2013285. doi: 10.1038/nrc1046.", "ArticleIdList": ["10.1038/nrc1046", "12671666"]}, {"Citation": "Robles A. I., Traverso G., Zhang M., et al. Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease\u2212Associated Colorectal Cancers. Gastroenterology . 2016;150(4):931\u2013943. doi: 10.1053/j.gastro.2015.12.036.", "ArticleIdList": ["10.1053/j.gastro.2015.12.036", "PMC5270616", "26764183"]}, {"Citation": "Meira L. B., Bugni J. M., Green S. L., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. The Journal of Clinical Investigation . 2008;118(7):2516\u20132525. doi: 10.1172/JCI35073.", "ArticleIdList": ["10.1172/JCI35073", "PMC2423313", "18521188"]}, {"Citation": "Gronke K., Hern\u00e1ndez P. P., Zimmermann J., et al. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature . 2019;566(7743):249\u2013253. doi: 10.1038/s41586-019-0899-7.", "ArticleIdList": ["10.1038/s41586-019-0899-7", "PMC6420091", "30700914"]}, {"Citation": "Schwitalla S., Fingerle A. A., Cammareri P., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell . 2013;152(1\u20132):25\u201338. doi: 10.1016/j.cell.2012.12.012.", "ArticleIdList": ["10.1016/j.cell.2012.12.012", "23273993"]}, {"Citation": "Arthur J. C., Perez-Chanona E., M\u00fchlbauer M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science . 2012;338(6103):120\u2013123. doi: 10.1126/science.1224820.", "ArticleIdList": ["10.1126/science.1224820", "PMC3645302", "22903521"]}, {"Citation": "Karin M., Greten F. R. NF-\u03baB: linking inflammation and immunity to cancer development and progression. Nature Reviews. Immunology . 2005;5(10):749\u2013759. doi: 10.1038/nri1703.", "ArticleIdList": ["10.1038/nri1703", "16175180"]}, {"Citation": "Grivennikov S., Karin E., Terzic J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell . 2009;15(2):103\u2013113. doi: 10.1016/j.ccr.2009.01.001.", "ArticleIdList": ["10.1016/j.ccr.2009.01.001", "PMC2667107", "19185845"]}, {"Citation": "Dunn G. P., Old L. J., Schreiber R. D. The three Es of cancer immunoediting. Annual Review of Immunology . 2004;22(1):329\u2013360. doi: 10.1146/annurev.immunol.22.012703.104803.", "ArticleIdList": ["10.1146/annurev.immunol.22.012703.104803", "15032581"]}, {"Citation": "Schreiber R. D., Old L. J., Smyth M. J. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science . 2011;331(6024):1565\u20131570. doi: 10.1126/science.1203486.", "ArticleIdList": ["10.1126/science.1203486", "21436444"]}, {"Citation": "Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews. Cancer . 2009;9(11):798\u2013809. doi: 10.1038/nrc2734.", "ArticleIdList": ["10.1038/nrc2734", "PMC4856025", "19851315"]}, {"Citation": "Ziegler P. K., Bollrath J., Pallangyo C. K., et al. Mitophagy in intestinal epithelial cells triggers adaptive immunity during tumorigenesis. Cell . 2018;174(1):88\u2013101.e16. doi: 10.1016/j.cell.2018.05.028.", "ArticleIdList": ["10.1016/j.cell.2018.05.028", "PMC6354256", "29909986"]}, {"Citation": "Iannello A., Raulet D. H. Immunosurveillance of senescent cancer cells by natural killer cells. Oncoimmunology . 2014;3(2, article e27616) doi: 10.4161/onci.27616.", "ArticleIdList": ["10.4161/onci.27616", "PMC4006855", "24800169"]}, {"Citation": "Lam A. R., le Bert N., Ho S. S. W., et al. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Research . 2014;74(8):2193\u20132203. doi: 10.1158/0008-5472.CAN-13-1703.", "ArticleIdList": ["10.1158/0008-5472.CAN-13-1703", "PMC4229084", "24590060"]}, {"Citation": "Shifrin N., Raulet D. H., Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Seminars in Immunology . 2014;26(2):138\u2013144. doi: 10.1016/j.smim.2014.02.007.", "ArticleIdList": ["10.1016/j.smim.2014.02.007", "PMC3984600", "24629893"]}, {"Citation": "Kuraishy A., Karin M., Grivennikov S. I. Tumor promotion via injury- and death-induced inflammation. Immunity . 2011;35(4):467\u2013477. doi: 10.1016/j.immuni.2011.09.006.", "ArticleIdList": ["10.1016/j.immuni.2011.09.006", "PMC3587290", "22035839"]}, {"Citation": "Zlatian O. M., Com\u0103nescu M. V., Ro\u015fu A. F., et al. Histochemical and immunohistochemical evidence of tumor heterogeneity in colorectal cancer. Romanian Journal of Morphology and Embryology . 2015;56(1):175\u2013181.", "ArticleIdList": ["25826503"]}, {"Citation": "Docea A. O., Mitru\u0163 P., Grigore D., Pirici D., C\u01celina D. C., Gofi\u0163\u01ce E. Immunohistochemical expression of TGF beta (TGF-\u03b2), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas. Romanian Journal of Morphology and Embryology . 2012;53(3):683\u2013692.", "ArticleIdList": ["23188426"]}, {"Citation": "Greten F. R., Eckmann L., Greten T. F., et al. IKK\u03b2 Links Inflammation and Tumorigenesis in a Mouse Model of Colitis- Associated Cancer. Cell . 2004;118(3):285\u2013296. doi: 10.1016/j.cell.2004.07.013.", "ArticleIdList": ["10.1016/j.cell.2004.07.013", "15294155"]}, {"Citation": "Becker C., Fantini M. C., Schramm C., et al. TGF-\u03b2 Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 _trans_ -Signaling. Immunity . 2004;21(4):491\u2013501. doi: 10.1016/j.immuni.2004.07.020.", "ArticleIdList": ["10.1016/j.immuni.2004.07.020", "15485627"]}, {"Citation": "Huber S., Gagliani N., Zenewicz L. A., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature . 2012;491(7423):259\u2013263. doi: 10.1038/nature11535.", "ArticleIdList": ["10.1038/nature11535", "PMC3493690", "23075849"]}, {"Citation": "Popivanova B. K., Kitamura K., Wu Y., et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. The Journal of Clinical Investigation . 2008;118(2):560\u2013570. doi: 10.1172/JCI32453.", "ArticleIdList": ["10.1172/JCI32453", "PMC2213370", "18219394"]}, {"Citation": "Putoczki T. L., Thiem S., Loving A., et al. Interleukin-11 is the dominant Il-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell . 2013;24(2):257\u2013271. doi: 10.1016/j.ccr.2013.06.017.", "ArticleIdList": ["10.1016/j.ccr.2013.06.017", "23948300"]}, {"Citation": "Sun Y., Kang C., Zhang A., et al. Co-delivery of dual-drugs with nanoparticle to overcome multidrug resistance. European Journal of BioMedical Research . 2016;2(2):p. 12. doi: 10.18088/ejbmr.2.2.2016.pp12-18.", "ArticleIdList": ["10.18088/ejbmr.2.2.2016.pp12-18"]}, {"Citation": "Espinosa E., Zamora P., Feliu J., Baron M. G. Classification of anticancer drugs--a new system based on therapeutic targets. Cancer Treatment Reviews . 2003;29(6):515\u2013523. doi: 10.1016/S0305-7372(03)00116-6.", "ArticleIdList": ["10.1016/S0305-7372(03)00116-6", "14585261"]}, {"Citation": "Sun T., Zhang Y. S., Pang B., Hyun D. C., Yang M., Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie, International Edition . 2014;53(46):12320\u201312364. doi: 10.1002/anie.201403036.", "ArticleIdList": ["10.1002/anie.201403036", "25294565"]}, {"Citation": "Scott A. M., Wolchok J. D., Old L. J. Antibody therapy of cancer. Nature Reviews. Cancer . 2012;12(4):278\u2013287. doi: 10.1038/nrc3236.", "ArticleIdList": ["10.1038/nrc3236", "22437872"]}, {"Citation": "D\u2019Incalci M., Badri N., Galmarini C. M., Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. British Journal of Cancer . 2014;111(4):646\u2013650. doi: 10.1038/bjc.2014.149.", "ArticleIdList": ["10.1038/bjc.2014.149", "PMC4134488", "24755886"]}, {"Citation": "Atmaca H., Bozkurt E., Uzunoglu S., Uslu R., Karaca B. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2\u2212/ER+) and MDA- MB-453 (HER2+/ER\u2212) breast cancer cells. Toxicology Letters . 2013;221(2):128\u2013136. doi: 10.1016/j.toxlet.2013.06.213.", "ArticleIdList": ["10.1016/j.toxlet.2013.06.213", "23792433"]}, {"Citation": "Scarpace S. L. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer. Clinical Therapeutics . 2012;34(7):1467\u20131473. doi: 10.1016/j.clinthera.2012.06.003.", "ArticleIdList": ["10.1016/j.clinthera.2012.06.003", "22739019"]}, {"Citation": "Zonder J. A., Shields A. F., Zalupski M., et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clinical Cancer Research . 2001;7(1):38\u201342.", "ArticleIdList": ["11205915"]}, {"Citation": "Liu J., Zhao D., He W., Zhang H., Li Z., Luan Y. Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy. Journal of colloid and interface science . 2017;487:239\u2013249. doi: 10.1016/j.jcis.2016.10.041.", "ArticleIdList": ["10.1016/j.jcis.2016.10.041", "27776282"]}, {"Citation": "Krege S., Rexer H., vom Dorp F., et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05) BJU International . 2014;113(3):429\u2013436. doi: 10.1111/bju.12437.", "ArticleIdList": ["10.1111/bju.12437", "24053564"]}, {"Citation": "Akashi Y., Oda T., Ohara Y., et al. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1. British Journal of Cancer . 2014;110(6):1481\u20131487. doi: 10.1038/bjc.2014.49.", "ArticleIdList": ["10.1038/bjc.2014.49", "PMC3960621", "24556620"]}, {"Citation": "Chen Z., Wang C., Li T. F., et al. Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates. Nanomedicine . 2019;14(3):335\u2013351. doi: 10.2217/nnm-2018-0330.", "ArticleIdList": ["10.2217/nnm-2018-0330", "30676239"]}, {"Citation": "Singla A. K., Garg A., Aggarwal D. Paclitaxel and its formulations. International Journal of Pharmaceutics . 2002;235(1-2):179\u2013192. doi: 10.1016/S0378-5173(01)00986-3.", "ArticleIdList": ["10.1016/S0378-5173(01)00986-3", "11879753"]}, {"Citation": "Hezari M., Croteau R. Taxol biosynthesis: an update. Planta Medica . 1997;63(4):291\u2013295. doi: 10.1055/s-2006-957684.", "ArticleIdList": ["10.1055/s-2006-957684", "9270370"]}, {"Citation": "Kampan N. C., Madondo M. T., McNally O. M., Quinn M., Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Research International . 2015;2015:21. doi: 10.1155/2015/413076.413076", "ArticleIdList": ["10.1155/2015/413076", "PMC4475536", "26137480"]}, {"Citation": "Desai A., Mitchison T. J. Microtubule polymerization dynamics. Annual Review of Cell and Developmental Biology . 1997;13(1):83\u2013117. doi: 10.1146/annurev.cellbio.13.1.83.", "ArticleIdList": ["10.1146/annurev.cellbio.13.1.83", "9442869"]}, {"Citation": "Schiff P. B., Horwit S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proceedings of the National Academy of Sciences of the United States of America . 1980;77(3):1561\u20131565. doi: 10.1073/pnas.77.3.1561.", "ArticleIdList": ["10.1073/pnas.77.3.1561", "PMC348536", "6103535"]}, {"Citation": "Lowenfels A. B., Maisonneuve P. Epidemiologic and etiologic factors of pancreatic cancer. Hematology/Oncology Clinics of North America . 2002;16(1):1\u201316. doi: 10.1016/S0889-8588(01)00003-X.", "ArticleIdList": ["10.1016/S0889-8588(01)00003-X", "12063821"]}, {"Citation": "Sharifi-Rad J., Rodrigues C. F., Sharopov F., et al. Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds. International Journal of Environmental Research and Public Health . 2020;17(7):p. 2326. doi: 10.3390/ijerph17072326.", "ArticleIdList": ["10.3390/ijerph17072326", "PMC7177934", "32235611"]}, {"Citation": "Midha S., Chawla S., Garg P. K. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Letters . 2016;381(1):269\u2013277. doi: 10.1016/j.canlet.2016.07.022.", "ArticleIdList": ["10.1016/j.canlet.2016.07.022", "27461582"]}, {"Citation": "Nandakumar A. National Cancer Registry Programme . New Delhi, India: Indian Council of Medical Research, Consolidated report of the population based cancer registries; 1990."}, {"Citation": "Boda D., Docea A. O., Calina D., et al. Human papilloma virus: apprehending the link with carcinogenesis and unveiling new research avenues (review) International Journal of Oncology . 2018;52(3):637\u2013655. doi: 10.3892/ijo.2018.4256.", "ArticleIdList": ["10.3892/ijo.2018.4256", "PMC5807043", "29393378"]}, {"Citation": "Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians . 2016;66(1):7\u201330. doi: 10.3322/caac.21332.", "ArticleIdList": ["10.3322/caac.21332", "26742998"]}, {"Citation": "Global Burden of Disease Cancer Collaboration, Fitzmaurice C., Allen C., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncology . 2017;3(4):524\u2013548. doi: 10.1001/jamaoncol.2016.5688.", "ArticleIdList": ["10.1001/jamaoncol.2016.5688", "PMC6103527", "27918777"]}, {"Citation": "Crocetti E., Mallone S., Robsahm T. E., et al. Survival of patients with skin melanoma in Europe increases further: results of the EUROCARE-5 study. European Journal of Cancer . 2015;51(15):2179\u20132190. doi: 10.1016/j.ejca.2015.07.039.", "ArticleIdList": ["10.1016/j.ejca.2015.07.039", "26421821"]}, {"Citation": "Jordan M. A., Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews. Cancer . 2004;4(4):253\u2013265. doi: 10.1038/nrc1317.", "ArticleIdList": ["10.1038/nrc1317", "15057285"]}, {"Citation": "Joerger M., Huitema A. D. R., Van Den Bongard D. H. J. G., Schellens J. H. M., Beijnen J. H. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of paclitaxel in patients with solid tumors. Clinical Cancer Research . 2006;12(7):2150\u20132157. doi: 10.1158/1078-0432.CCR-05-2069.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-2069", "16609028"]}, {"Citation": "American Cancer Society. \nCancer Facts & Figures\n. 2015.  \n https://www.cancer.org\n."}, {"Citation": "Arnold L. D., Patel A. V., Yan Y., et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiology, Biomarkers & Prevention . 2009;18(9):2397\u20132405. doi: 10.1158/1055-9965.EPI-09-0080.", "ArticleIdList": ["10.1158/1055-9965.EPI-09-0080", "PMC3630792", "19723915"]}, {"Citation": "Longnecker D. S., Karagas M. R., Tosteson T. D., Mott L. A. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in asians, blacks, and whites in the United States. Pancreas . 2000;21(4):338\u2013343.", "ArticleIdList": ["11075987"]}, {"Citation": "Huang J. Y., Wang R., Gao Y. T., Yuan J. M. ABO blood type and the risk of cancer\u2014findings from the Shanghai Cohort Study. PLoS One . 2017;12(9):1\u201312. doi: 10.1371/journal.pone.0184295.", "ArticleIdList": ["10.1371/journal.pone.0184295", "PMC5589178", "28880901"]}, {"Citation": "Donaldson M. S. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutrition Journal . 2004;3(1):1\u201321. doi: 10.1186/1475-2891-3-19.", "ArticleIdList": ["10.1186/1475-2891-3-19", "PMC526387", "15496224"]}, {"Citation": "Salehi B., Rescigno A., Dettori T., et al. Avocado-soybean unsaponifiables: a panoply of potentialities to be exploited. Biomolecules . 2020;10(1):p. 130. doi: 10.3390/biom10010130.", "ArticleIdList": ["10.3390/biom10010130", "PMC7023362", "31940989"]}, {"Citation": "Allen N., Anderson L. M., Beland F. A., et al. Alcohol consumption and ethyl carbamate. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans . 2010;96:1\u20131379.", "ArticleIdList": ["PMC4781168", "21735939"]}, {"Citation": "Bagnardi V., Rota M., Botteri E., et al. Light alcohol drinking and cancer: a meta-analysis. Annals of Oncology . 2013;24(2):301\u2013308. doi: 10.1093/annonc/mds337.", "ArticleIdList": ["10.1093/annonc/mds337", "22910838"]}, {"Citation": "Nelson D. E., Jarman D. W., Rehm J., et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. American Journal of Public Health . 2013;103(4):641\u2013648. doi: 10.2105/AJPH.2012.301199.", "ArticleIdList": ["10.2105/AJPH.2012.301199", "PMC3673233", "23409916"]}, {"Citation": "LoConte N. K., Brewster A. M., Kaur J. S., Merrill J. K., Alberg A. J. Alcohol and cancer: a statement of the American Society of Clinical Oncology. Journal of Clinical Oncology . 2018;36(1):83\u201393.", "ArticleIdList": ["29112463"]}, {"Citation": "Wu C., Wang Z., Song X., et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nature Genetics . 2014;46(9):1001\u20131006. doi: 10.1038/ng.3064.", "ArticleIdList": ["10.1038/ng.3064", "PMC4212832", "25129146"]}, {"Citation": "Grewal P., Viswanathen V. A. Liver cancer and alcohol. Clinics in Liver Disease . 2012;16(4):839\u2013850.", "ArticleIdList": ["23101985"]}, {"Citation": "Fedirko V., Tramacere I., Bagnardi V., et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Annals of Oncology . 2011;22(9):1958\u20131972. doi: 10.1093/annonc/mdq653.", "ArticleIdList": ["10.1093/annonc/mdq653", "21307158"]}, {"Citation": "Mackay J., Mensah G. A., Mendis S., Greenlund K. The Atlas of Heart Disease and Stroke . Geneva: World Health Organization; 2004."}, {"Citation": "Murthy N. S., Rajaram D., Gautham M. S., Shivaraj N. S., Nandakumar B. S., Pruthvish S. Risk of cancer development in India. Asian Pacific Journal of Cancer Prevention . 2011;12(2):387\u2013391.", "ArticleIdList": ["21545200"]}, {"Citation": "Doll R., Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. JNCI: Journal of the National Cancer Institute . 1981;66(6):1192\u20131308. doi: 10.1093/jnci/66.6.1192.", "ArticleIdList": ["10.1093/jnci/66.6.1192", "7017215"]}, {"Citation": "Fan J. H., Wang J. B., Jiang Y., et al. Attributable causes of liver cancer mortality and incidence in China. Asian Pacific Journal of Cancer Prevention . 2013;14(12):7251\u20137256. doi: 10.7314/APJCP.2013.14.12.7251.", "ArticleIdList": ["10.7314/APJCP.2013.14.12.7251", "24460283"]}, {"Citation": "Pisani P., Parkin D. M., Mu\u00f1oz N., Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiology and Prevention Biomarkers . 1997;6(6):387\u2013400.", "ArticleIdList": ["9184771"]}, {"Citation": "Parkin D. M. The global health burden of infection-associated cancers in the year 2002. International Journal of Cancer . 2006;118(12):3030\u20133044.", "ArticleIdList": ["16404738"]}, {"Citation": "de Martel C., Ferlay J., Franceschi S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology . 2012;13(6):607\u2013615. doi: 10.1016/S1470-2045(12)70137-7.", "ArticleIdList": ["10.1016/S1470-2045(12)70137-7", "22575588"]}, {"Citation": "Sani T. A., Mohammadpour E., Mohammadi A., et al. Cytotoxic and apoptogenic properties of Dracocephalum kotschyi aerial part different fractions on calu-6 and mehr-80 lung cancer cell lines. Farm\u00e1cia . 2017;65(2):189\u2013199."}, {"Citation": "Weinstein J. N. Pharmacogenomics\u2014teaching old drugs new tricks. The New England Journal of Medicine . 2000;343(19):1408\u20131409.", "ArticleIdList": ["11070107"]}, {"Citation": "Salehi B., del Prado-Audelo M. L., Cort\u00e9s H., et al. Therapeutic applications of curcumin nanomedicine formulations in cardiovascular diseases. Journal of Clinical Medicine . 2020;9(3):p. 746. doi: 10.3390/jcm9030746.", "ArticleIdList": ["10.3390/jcm9030746", "PMC7141226", "32164244"]}, {"Citation": "Carter P. Improving the efficacy of antibody-based cancer therapies. Nature Reviews. Cancer . 2001;1(2):118\u2013129.", "ArticleIdList": ["11905803"]}, {"Citation": "Goldenberg D. M. Targeted therapy of cancer with radiolabeled antibodies. Journal of Nuclear Medicine . 2002;43(5):693\u2013713.", "ArticleIdList": ["11994535"]}, {"Citation": "Reichert J. M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Current Opinion in Molecular Therapeutics . 2002;4(2):110\u2013118.", "ArticleIdList": ["12044031"]}, {"Citation": "Ross J. S., Schenkein D. P., Pietrusko R., et al. Targeted therapies for cancer 2004. American Journal of Clinical Pathology . 2004;122(4):598\u2013609. doi: 10.1309/5CWPU41AFR1VYM3F.", "ArticleIdList": ["10.1309/5CWPU41AFR1VYM3F", "15487459"]}, {"Citation": "Reilly R. M., Sandhu J., Alvarez-Diez T. M., Gallinger S., Kirsh J., Stern H. Problems of delivery of monoclonal antibodies: pharmaceutical and pharmacokinetic solutions. Clinical Pharmacokinetics . 1995;28(2):126\u2013142.", "ArticleIdList": ["7736688"]}, {"Citation": "Fronier M., Risio M., Poznak C. V., Seidman A. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology . 2002;16(10):1340\u20131348.", "ArticleIdList": ["12435204"]}, {"Citation": "Barbuti A. M., Chen Z. S. Paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers . 2015;7(4):2360\u20132371.", "ArticleIdList": ["PMC4695897", "26633515"]}, {"Citation": "Isah T. Natural sources of Taxol. Journal of Pharmaceutical Research International . 2015;6(4):214\u2013227."}, {"Citation": "Hoffman A., Shahidi F. Paclitaxel and other taxanes in hazelnut. Journal of Functional Foods . 2009;1(1):33\u201337."}, {"Citation": "Hagiwara H., Sunada Y. Mechanism of taxane neurotoxicity. Breast Cancer . 2004;11(1):82\u201385.", "ArticleIdList": ["14718798"]}, {"Citation": "Francis P. A., Kris M. G., Rigas J. R., Grant S. C., Miller V. A. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer . 1995;12(1):S163\u2013S172.", "ArticleIdList": ["7551925"]}, {"Citation": "Lyseng-Williamson K. A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs . 2005;65(17):2513\u20132531.", "ArticleIdList": ["16296875"]}, {"Citation": "Malhotra M., Dhingra R., Sharma T., et al. Cabazitaxel: a novel drug for hormone-refractory prostate cancer. Mini Reviews in Medicinal Chemistry . 2013;13(6):915\u2013920. doi: 10.2174/1389557511313060011.", "ArticleIdList": ["10.2174/1389557511313060011", "22950608"]}, {"Citation": "Adachi A., Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. The Journal of Dermatology . 2007;34(7):473\u2013476.", "ArticleIdList": ["17584326"]}, {"Citation": "Wong N. Y., Parsons L. M., Trotter M. J., Tsang R. Y. Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report. BMC Research Notes . 2014;7:p. 785.", "ArticleIdList": ["PMC4232622", "25369825"]}, {"Citation": "Sibaud V., Leb\u0153uf N. R., Roche H., et al. Dermatological adverse events with taxane chemotherapy. European Journal of Dermatology . 2016;26(5):427\u2013443. doi: 10.1684/ejd.2016.2833.", "ArticleIdList": ["10.1684/ejd.2016.2833", "PMC5526115", "27550571"]}, {"Citation": "Pezzani R., Salehi B., Vitalini S., et al. Synergistic effects of plant derivatives and conventional chemotherapeutic agents: an update on the cancer perspective. Medicina . 2019;55(4):p. 110. doi: 10.3390/medicina55040110.", "ArticleIdList": ["10.3390/medicina55040110", "PMC6524059", "30999703"]}, {"Citation": "Klimaszewska-Wisniewska A., Halas-Wisniewska M., Tadrowski T., Gagat M., Grzanka D., Grzanka A. Paclitaxel and the dietary flavonoid fisetin: a synergistic combination that induces mitotic catastrophe and autophagic cell death in A549 non-small cell lung cancer cells. Cancer Cell International . 2016;16:p. 10.", "ArticleIdList": ["PMC4754822", "26884726"]}, {"Citation": "Nakao Y., Fusetani N. Marine invertebrates: sponges. In: Hung-Wen L., Mander L., editors. Comprehensive Natural Products II . Elsevier; 2010. pp. 327\u2013362."}, {"Citation": "Huang G. S., Lopez-Barcons L., Freeze B. S., et al. Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice. Clinical Cancer Research . 2006;12(1):298\u2013304. doi: 10.1158/1078-0432.CCR-05-0229.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-0229", "PMC4039036", "16397055"]}, {"Citation": "Yang J. C., Lu M. C., Lee C. L., et al. Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radical Biology & Medicine . 2011;51(3):641\u2013657. doi: 10.1016/j.freeradbiomed.2011.05.012.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.05.012", "21641992"]}, {"Citation": "Effendi W. I., Nagano T., Tachihara M., et al. Synergistic interaction of gemcitabine and paclitaxel by modulating acetylation and polymerization of tubulin in non-small cell lung cancer cell lines. Cancer Management and Research . 2019;Volume 11:3669\u20133679. doi: 10.2147/CMAR.S193789.", "ArticleIdList": ["10.2147/CMAR.S193789", "PMC6500879", "31118789"]}, {"Citation": "Shafer A., Zhou C., Gehrig P. A., Boggess J. F., Bae-Jump V. L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. International Journal of Cancer . 2010;126(5):1144\u20131154.", "ArticleIdList": ["PMC2818608", "19688827"]}, {"Citation": "Wu Z. H., Ke L. M., Hu L. Y., Li X. Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One . 2012;7(12, article e51721)", "ArticleIdList": ["PMC3520897", "23251610"]}, {"Citation": "Sharifi-Rad J., Quispe C., Butnariu M., et al. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell International . 2021;21(1):1\u201321. doi: 10.1186/s12935-021-02025-4.", "ArticleIdList": ["10.1186/s12935-021-02025-4", "PMC8223345", "34167552"]}, {"Citation": "Liao J., Jia Y., Wu Y., et al. Physical-, chemical-, and biological-responsive nanomedicine for cancer therapy. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology . 2020;12(1, article e1581) doi: 10.1002/wnan.1581.", "ArticleIdList": ["10.1002/wnan.1581", "31429208"]}, {"Citation": "Grodzinski P., Kircher M., Goldberg M., Gabizon A. Integrating nanotechnology into cancer care. ACS Nano . 2019;13(7):7370\u20137376.", "ArticleIdList": ["31240914"]}, {"Citation": "Peters C., Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Reports . 2015;35, article e00225", "ArticleIdList": ["PMC4613712", "26182432"]}, {"Citation": "McGuire W. P., Rowinsky E. K., Rosenshein N. B., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine . 1989;111(4):273\u2013279. doi: 10.7326/0003-4819-111-4-273.", "ArticleIdList": ["10.7326/0003-4819-111-4-273", "2569287"]}, {"Citation": "Ozols R. F., Bundy B. N., Greer B. E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. Journal of Clinical Oncology . 2003;21(17):3194\u20133200. doi: 10.1200/JCO.2003.02.153.", "ArticleIdList": ["10.1200/JCO.2003.02.153", "12860964"]}, {"Citation": "Gadducci A., Katsaros D., Zola P., et al. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (after-6 protocol 2) International Journal of Gynecological Cancer . 2009;19(4):615\u2013619. doi: 10.1111/IGC.0b013e3181a4476b.", "ArticleIdList": ["10.1111/IGC.0b013e3181a4476b", "19509559"]}, {"Citation": "Bhatt R. S., Merchan J., Parker R., et al. A phase 2 pilot trial of low-dose, continuous infusion, or \u201cmetronomic\u201d paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer . 2010;116(7):1751\u20131756. doi: 10.1002/cncr.24902.", "ArticleIdList": ["10.1002/cncr.24902", "PMC2847062", "20120033"]}, {"Citation": "Caballero M., Grau J. J., Blanch J. L., et al. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) paclitaxel treatment for advanced head and neck cancer. Archives of Otolaryngology \u2013 Head & Neck Surgery . 2007;133(11):1143\u20131148. doi: 10.1001/archotol.133.11.1143.", "ArticleIdList": ["10.1001/archotol.133.11.1143", "18025320"]}, {"Citation": "Li R., Huang W., Wang X., Liu X., Xu Z. Effects of yellow, green, and different blue spectra on growth of potato plantlets in vitro. HortScience . 2018;53(4):541\u2013546. doi: 10.21273/HORTSCI12848-18.", "ArticleIdList": ["10.21273/HORTSCI12848-18"]}, {"Citation": "Li X., Kwon H. Efficacy and safety of nanoparticle albumin-bound paclitaxel in elderly patients with metastatic breast cancer: a meta-analysis. Journal of Clinical Medicine . 2019;8(10):p. 1689.", "ArticleIdList": ["PMC6832596", "31618921"]}, {"Citation": "Lu H., Zha S., Zhang W., et al. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. BMC Cancer . 2021;21(1):p. 830. doi: 10.1186/s12885-021-08441-z.", "ArticleIdList": ["10.1186/s12885-021-08441-z", "PMC8286600", "34275458"]}, {"Citation": "Gelderblom H., Verweij J., Nooter K., Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer . 2001;37(13):1590\u20131598.", "ArticleIdList": ["11527683"]}, {"Citation": "Bernabeu E., Cagel M., Lagomarsino E., Moretton M., Chiappetta D. A. Paclitaxel: what has been done and the challenges remain ahead. International Journal of Pharmaceutics . 2017;526:474\u2013495.", "ArticleIdList": ["28501439"]}, {"Citation": "Fan L., Wy H., Zhang H., Yang T. H. pH-sensitive podophyllotoxin carrier for cancer cells specific delivery. Polymer Composites . 2010;31:51\u201359."}, {"Citation": "Thamake S., Raut S. L., Gryczynski Z., Ranjan A. P., Vishwanatha J. K. Alendronate coated poly lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials . 2012;33:7164\u20137173.", "ArticleIdList": ["22795543"]}, {"Citation": "Gradishar W. J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology . 2005;23(31):7794\u20137803. doi: 10.1200/JCO.2005.04.937.", "ArticleIdList": ["10.1200/JCO.2005.04.937", "16172456"]}, {"Citation": "Dranitsaris G., Cottrell W., Spirovski B., Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. Journal of Oncology Pharmacy Practice . 2009;15(2):67\u201378. doi: 10.1177/1078155208098584.", "ArticleIdList": ["10.1177/1078155208098584", "19036903"]}, {"Citation": "Dranitsaris G., Coleman R., Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Research and Treatment . 2010;119(3):717\u2013724. doi: 10.1007/s10549-009-0424-z.", "ArticleIdList": ["10.1007/s10549-009-0424-z", "19495958"]}, {"Citation": "Garcia S. C., Guterres S. S., Bubols G. B., Bulc\u00e3o R. P., Char\u00e3o M. F., Pohlmann A. R. Polymeric nanoparticles: in vivo toxicological evaluation, cardiotoxicity, and hepatotoxicity. In: Dur\u00e1n N., Guterres S. S., Alves O. L., editors. Nanotoxicology: Materials, Methodologies, and Assessments . New York: Springer; 2014. pp. 299\u2013324."}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "5", "Day": "26"}, {"Year": "2021", "Month": "9", "Day": "14"}, {"Year": "2021", "Month": "10", "Day": "28", "Hour": "6", "Minute": "39"}, {"Year": "2021", "Month": "10", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "2", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["34707776", "PMC8545549", "10.1155/2021/3687700"]}}], "PubmedBookArticle": []}